Genetic testing services provider Invitae (NVTA -4.8%) slips on below-average volume in apparent response to a new (but not yet posted) report from independent research shop Hedgeye that sees a 30 – 50% downside in shares.
The stock is currently exchanging hands at $18.14, down 37% from the all-time high of $28.75 on August 7.
Q3 revenue was up 51% to $56.5M, $1.7M above consensus.
Q4 views expect a loss/share of ($0.67) on revenue of $69.2M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.